Vestmark Advisory Solutions Inc. Has $3.92 Million Stock Position in Sanofi $SNY

Key Points

• Vestmark Advisory Solutions Inc. increased its holdings in Sanofi by 101.6%, now owning 70,732 shares worth approximately $3.9 million.
• Several hedge funds have also increased their stakes in Sanofi, with Eastern Bank raising its position by 121% this quarter.
• Sanofi's latest earnings report revealed $0.90 EPS, missing estimates, although revenue exceeded expectations at $11.34 billion.

Vestmark Advisory Solutions Inc. grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 101.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,732 shares of the company's stock after purchasing an additional 35,644 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Sanofi were worth $3,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Neuberger Berman Group LLC boosted its stake in Sanofi by 85.7% in the first quarter. Neuberger Berman Group LLC now owns 37,216 shares of the company's stock worth $2,064,000 after purchasing an additional 17,175 shares in the last quarter. GQG Partners LLC acquired a new position in Sanofi in the first quarter worth $202,000. Regal Partners Ltd boosted its stake in Sanofi by 5.4% in the first quarter. Regal Partners Ltd now owns 765,366 shares of the company's stock worth $42,447,000 after purchasing an additional 38,981 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Sanofi by 18.1% in the first quarter. Russell Investments Group Ltd. now owns 453,236 shares of the company's stock worth $25,136,000 after purchasing an additional 69,559 shares in the last quarter. Finally, Callan Family Office LLC boosted its stake in Sanofi by 0.5% in the first quarter. Callan Family Office LLC now owns 71,602 shares of the company's stock worth $3,971,000 after purchasing an additional 362 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the topic of several research reports. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Barclays reissued an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $62.00.

Sanofi Stock Up 0.1%

SNY stock traded up $0.07 during trading hours on Monday, reaching $49.84. 3,945,271 shares of the stock were exchanged, compared to its average volume of 2,659,869. The company has a market cap of $122.38 billion, a price-to-earnings ratio of 11.98, a PEG ratio of 1.19 and a beta of 0.48. The firm's 50-day moving average is $48.57 and its 200-day moving average is $51.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi's revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.73 EPS. On average, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.